2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.
Date
2020-05-01Author
Bešlija, SemirGojković, Zdenka
Cerić, Timur
Mekić Abazović, Alma
Marijanović, Inga
Vranić, Semir
Mustedanagić-Mujanović, Jasminka
Skenderi, Faruk
Rakita, Ivanka
Guzijan, Aleksandar
Koprić, Dijana
Humačkić, Alen
Trokić, Danijela
Alidžanović, Jasmina
Efendić, Alma
Šišić, Ibrahim
Drljević, Harun
Bešlagić, Vanesa
Babić, Božana
Pašić, Azra
Ramić, Anela
Mikić, Dijana
Guzin, Zlatko
Karan, Dragana
Buhovac, Teo
Miletić, Dragana
Šečić, Senad
Đozić Šahmić, Azra
Mujbegović, Lejla
Kubura, Alisa
Burina, Mensura
Lalović, Nenad
Dukić, Nikolina
Vladičić Mašić, Jelena
Ćuk, Mirjana
Stanušić, Rajna
...show more authors ...show less authors
Metadata
Show full item recordAbstract
The HERe2cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist.
Collections
- Medicine Research [1482 items ]